Clinical trials: Brain Structure
Urea Cycle Disorder, Crigler-Najjar Syndrome
HepaStem Long-Term Safety Registry
All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences
- Conditions
- Urea Cycle Disorder, Crigler-Najjar Syndrome, Acute on Chronic Liver Failure
- Trial name
- PROLONGSTEM (NCT03343756)
- Where
- 29 sites in Belgium, Bulgaria and 3 more
- Volunteers
- 44 people
- Sponsor
- Cellaion SA
HER2-positive Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
- Trial name
- BREnnA (NCT07413939)
- Testing
- RO7771950, Tucatinib, Trastuzumab
- Where
- 206 sites in United States, Argentina and 23 more
- Volunteers
- 650 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
The purpose of this survey is to evaluate the long-term safety of Rasagiline (AZILECT) in patients with Parkinson's disease in daily clinical practice and also collect efficacy information.
- Trial name
- NCT03727139
- Testing
- Rasagiline
- Where
- Japan
- Volunteers
- 1,021 people
- Sponsor
- Takeda
Parkinson Disease
LRRK2 Mutation and Parkinson's Disease
The Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in autosomal dominant Parkinson's disease (PKD). An inhibitor for the leucine-rich repeat kinase 2 (LRRK2) is in pre-clinical development for potential use in treating…
- Trial name
- NCT01424475
- Testing
- Healthy, PKD Patients
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer Survivors, Healthy Participant
A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system)…
- Conditions
- Cancer Survivors, Healthy Participant, Elderly
- Trial name
- GIANTS-1 (NCT07363057)
- Testing
- GI-102 in combination with GIB-7
- Where
- 2 sites in Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GI Innovation, Inc.
Epilepsy, Epilepsy, Generalized
Clobazam in Subjects With Lennox-Gastaut Syndrome
The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut…
- Conditions
- Epilepsy, Epilepsy, Generalized, Seizures
- Trial name
- NCT00162981
- Testing
- Clobazam Low Dose, Clobazam High Dose
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Lundbeck LLC
Dwarfism, Growth Hormone Deficiency
Drug Use Investigation of Somatropin for GHD-ADULTS.
Post marketing drug use investigation of Genotropin for GHD-ADULTS.
- Trial name
- NCT00601419
- Testing
- Somatropin
- Volunteers
- 230 people
- Sponsor
- Pfizer
Amblyopia
A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia
It aims to find the effectiveness and the safety of Virtual Reality (Caterna, DOBOSO, item code: SJ-VRS2018) to facilitate amblyopia treatment combining spectacles and occlusion.
- Trial name
- VRTA (NCT04238065)
- Testing
- Caterna Virtual Reality, Spectacles(Best optical corrected distance vision), Patch
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Guangzhou Shijing Medical Software
Growth
BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)
The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months of age.
- Trial name
- NCT04957992
- Testing
- Control Infant Formula, Control Toddler Drink, Experimental Infant Formula
- Where
- 42 sites in United States
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Cerebrovascular Accident
Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial…
- Trial name
- NCT00274586
- Testing
- Aggrenox® modified release capsules
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment
Efficacy of MEMORMAX in Subjects With MCI
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment.
- Trial name
- ABO-MEMO (NCT03581929)
- Testing
- Memormax
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Aboca Spa Societa' Agricola
Concussion, Mild, TBI (Traumatic Brain Injury)
Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment
mTBI is widely recognized as a major public health concern in the United States and worldwide. mTBI diagnosis remains a clinical challenge as no single test can diagnose every concussion.
- Conditions
- Concussion, Mild, TBI (Traumatic Brain Injury), Mild Traumatic Brain Injury
- Trial name
- NCT03265912
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- ElMindA Ltd
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a 10-day treatment period with Posiphen® in subjects with amnestic MCI.
- Trial name
- NCT01072812
- Testing
- Posiphen® tartrate capsules
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Annovis Bio Inc.
Classic Galactosemia
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).
- Trial name
- NCT04902781
- Testing
- AT-007
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Applied Therapeutics, Inc.
Acromegaly
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
- Trial name
- NCT00635765
- Testing
- C2L-OCT-01 PR 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 63 people
- Sponsor
- Ambrilia Biopharma, Inc.
Alzheimer's Disease
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
This study evaluated the safety and efficacy of 10 cm^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm^2 for at…
- Trial name
- ADEPT (NCT00561392)
- Testing
- Rivastigmine 5 and 10 cm^2 patch
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Novartis
Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.
- Trial name
- PRIMARYS (NCT00690898)
- Testing
- Lanreotide autogel 120 mg
- Where
- 27 sites in Belgium, Czechia and 7 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Photosensitive Epilepsy
A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy
The purpose of this study is to check the Effects of JNJ-26489112 on the Photic Induced Paroxysmal electroencephalogram (EEG) Response in Patients with Photosensitive Epilepsy.
- Trial name
- NCT00579384
- Testing
- JNJ-26489112
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Parkinson's Syndrome
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian…
- Trial name
- NCT01950455
- Testing
- NAV5001
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Navidea Biopharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.